Lake Zurich-based Fresenius Kabi Thursday announced the immediate availability in the U.S. of Stimufend, a drug similar to Neulasta, for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications.
Related posts
-
Willow Creek worshipers gather on Christmas Eve
Willow Creek Community Church members came together on Tuesday to experience the hope and peace of... -
Santa, firefighters bring Christmas cheer to Elgin family
Santa Claus and a team of Elgin firefighters brought gifts to an Elgin family on Tuesday. -
Naperville woman dies after crash
A 38-year-old woman was killed Monday night when her SUV left the road and struck two...